VivoSense
VivoSense is a clinical trial solutions provider that focuses on the integration of wearable and connected technologies. They offer end-to-end services and scientific expertise for the implementation of these technologies in clinical trials. Their services include design and configuration, data generation, collection, and cleaning, as well as interpretation and delivery of insights. The company aims to improve patients' lives by transforming clinical trials through the capture, cleaning, and analysis of digital endpoints from wearable devices, utilizing their cloud platform and expert team.
VivoSense
VivoSense is a clinical trial solutions provider that focuses on the integration of wearable and connected technologies. They offer end-to-end services and scientific expertise for the implementation of these technologies in clinical trials. Their services include design and configuration, data generation, collection, and cleaning, as well as interpretation and delivery of insights. The company aims to improve patients' lives by transforming clinical trials through the capture, cleaning, and analysis of digital endpoints from wearable devices, utilizing their cloud platform and expert team.
TL;DR
What they do: Provide an end-to-end platform and services to generate validated digital clinical measures and wearable-sensor-derived biomarkers for regulated clinical trials
Headquarters: Newport Coast / Newport Beach, California, United States
Employees: 37
Notable funding: $25M Series A; additional grant funding reported
Company Overview
Problem Domain
Digital biomarkers, wearable sensor data analysis, and validated digital endpoints for clinical research
Industry
Health / Clinical Research / Digital Biomarkers
Funding Track Record
$25,000,000
Company announcement reports closing of a $25M Series A co-led by PXV and Debiopharm Innovation Fund
Company profiles list grant funding and institutional support
Investor Signal
“Co-led Series A by Perceptive Xontogeny (PXV) Fund and Debiopharm Innovation Fund; additional grants from National Institute on Aging and MassAITC”